Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Stocks Settle Mixed on Weakness in Tech Stocks

The S&P 500 Index ($SPX ) (SPY ) Monday closed down -0.31%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.67%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.15%. Stock indexes...

$SPX : 5,460.48 (-0.41%)
SPY : 544.22 (-0.39%)
$DOWI : 39,118.86 (-0.12%)
DIA : 391.13 (-0.11%)
$IUXX : 19,682.87 (-0.54%)
QQQ : 479.11 (-0.52%)
ZNU24 : 109-185 (-0.37%)
SMCI : 819.35 (-7.98%)
NVDA : 123.54 (-0.36%)
QCOM : 199.18 (+2.07%)
MRVL : 69.90 (+1.70%)
AVGO : 1,605.53 (+1.19%)
RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall, Monday, 6/24/2024

Stocks that traded heavily or had substantial price changes on Monday: RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall

UAA : 6.67 (-2.63%)
DIS : 99.29 (-2.82%)
SON : 50.72 (-1.78%)
RMD : 191.42 (-0.08%)
ALNY : 243.00 (-1.62%)
Stocks Mixed as Chip Stock Weakness Weighs on the Nasdaq 100

The S&P 500 Index ($SPX ) (SPY ) today is up +0.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.01%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.57%. Stock indexes today are mixed,...

$SPX : 5,460.48 (-0.41%)
SPY : 544.22 (-0.39%)
$DOWI : 39,118.86 (-0.12%)
DIA : 391.13 (-0.11%)
$IUXX : 19,682.87 (-0.54%)
QQQ : 479.11 (-0.52%)
ZNU24 : 109-185 (-0.37%)
SMCI : 819.35 (-7.98%)
NVDA : 123.54 (-0.36%)
QCOM : 199.18 (+2.07%)
MRVL : 69.90 (+1.70%)
AMAT : 235.99 (+1.49%)
Equity Market Indexes are Mixed Today Due to Tech Stock Weakness

The S&P 500 Index ($SPX ) (SPY ) today is up +0.24%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.99%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.34%. Stock indexes today are mixed....

$SPX : 5,460.48 (-0.41%)
SPY : 544.22 (-0.39%)
$DOWI : 39,118.86 (-0.12%)
DIA : 391.13 (-0.11%)
$IUXX : 19,682.87 (-0.54%)
QQQ : 479.11 (-0.52%)
ZNU24 : 109-185 (-0.37%)
META : 504.22 (-2.95%)
IBM : 172.95 (+1.23%)
TGT : 148.04 (+0.90%)
RXO : 26.15 (+4.85%)
ALNY : 243.00 (-1.62%)
Alnylam: Q1 Earnings Snapshot

Alnylam: Q1 Earnings Snapshot

ALNY : 243.00 (-1.62%)
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

/CNW/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets,...

ALNY : 243.00 (-1.62%)
Why Alnylam Pharmaceuticals Stock Is Sinking Today

Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.

BMO : 83.85 (+0.66%)
ALNY : 243.00 (-1.62%)
Alnylam: Q4 Earnings Snapshot

Alnylam: Q4 Earnings Snapshot

ALNY : 243.00 (-1.62%)
Alnylam: Q3 Earnings Snapshot

Alnylam: Q3 Earnings Snapshot

ALNY : 243.00 (-1.62%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such...

ALNY : 243.00 (-1.62%)

Barchart Exclusives

A Decade from Now, You'll Wish You Had Bought This Growth Stock
Strong revenue growth and product innovations have Wall Street believing that this growth stock will rally 114% over the next 12 months. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar